Health care expenditures from living longer-how much do they matter

International Journal of Health Planning and Management

Volumn 29, Issue 1, 2014, Pages 43-51

  Gandjour, Afschin ^a,b  

^a FRANKFURT SCHOOL OF FINANCE AND MANAGEMENT   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bias; Economic evaluation; Life extension costs; Savings

Indexed keywords

COST-BENEFIT ANALYSIS; DISEASE CONTROL; HEALTH EXPENDITURE; LIFE EXPECTANCY; MORBIDITY; MORTALITY; SAMPLING BIAS; VALUATION;

UNITED STATES;

AGED; ECONOMIC MODEL; ECONOMICS; EPIDEMIOLOGY; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MALE; MEDICARE; MORBIDITY; MORTALITY; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LIFE EXPECTANCY; MALE; MEDICARE; MODELS, ECONOMIC; MORBIDITY; MORTALITY; UNITED STATES;

EID: 84895508711     PISSN: 07496753     EISSN: 10991751     Source Type: Journal    
DOI: 10.1002/hpm.2164     Document Type: Article

References (33)

1. Adler GS. 1994. A profile of the Medicare Current Beneficiary Survey. Health Care Financ. Rev. 15:153-163.
2. CDC Centers for Disease Control and Prevention. 2011. United States life tables. http://www.cdc.gov/nchs/products/life_tables.htm#life [26 August 2011].
3. Chernew ME, Goldman DP, Pan F, Shang B. 2005. Disability and health care spending among Medicare beneficiaries. Health Aff. 24 Suppl 2:W5R42-52.
4. Denton FT, Gafni A, Spencer BG. 2002. Exploring the effects of population change on the costs of physician services. J. Health Econ. 21(5):781-803.
5. Feenstra TL, van Baal PH, Gandjour A, Brouwer WB. 2008. Future costs in economic evaluation. A comment on Lee. J Health Econ. 27(6):1645-1649.
6. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. 2007. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N. Engl. J. Med. 356(23):2388-98.
7. Fuchs VR. 1984. "Though much is taken": reflections on aging, health, and medical care. Milbank Mem. Fund Q. Health Soc. 62(2):143-166.
8. Gandjour A, Lauterbach KW. 2005. Does prevention save costs? Considering deferral of the expensive last year of life. J. Health Econ. 24(4):715-724.
9. Gandjour A. 2006. Consumption costs and earnings during added years of life-a reply to Nyman. Health Econ. 15(3):315-317.
10. Gandjour A, Ihle P, Schubert I. 2008. Impact of demographic changes on health care expenditure in Germany: an analysis considering the expenditures of decedents. Gesundheitswesen 70(2):77-80.
11. Gandjour A. 2009. Aging diseases-do they prevent preventive health care from saving costs? Health Econ. 18(3):355-362.
12. Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CP. 2010. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit. Pathw. Cardiol. 9(1):14-18.
13. Kolm P, Yuan Y, Veledar E, Mehta SR, O'Brien JA, Weintraub WS. 2007. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. Can. J. Cardiol. 23(13):1037-1042.
14. Kruse M, Sørensen J, Gyrd-Hansen D. 2010. Future costs in cost-effectiveness analysis: an empirical assessment. Eur. J. Health Econ. Sep 28.
15. Lee R, Tuljapurkar S. 1998. Uncertain demographic futures and social security finance. Am. Econ. Rev. 88:237-241.
16. Lee R, Skinner J. 1999. Will aging baby boomers bust the federal budget? J. Econ. Perspect. 13(1):117-140.
17. Lee RH. 2008, Future costs in cost effectiveness analysis. J. Health Econ. 27(4):809-18.
18. Levinsky NG, Yu W, Ash A, Moskowitz M, Gazelle G, Saynina O, Emanuel EJ. 2001. Influence of age on Medicare expenditures and medical care in the last year of life. JAMA 286:1349-1355.
19. Liljas B, Karlsson GS, Stålhammar NO. 2008. On future non-medical costs in economic evaluations. Health Econ. 17(5):579-591.
20. Lipscomb J, Weinstein MC, Torrance GW. 1996. Time preference. In: Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Oxford University Press: Oxford; 214-235.
21. Lubitz J, Cai L, Kramarow E, Lentzner H. 2003. Health, life expectancy, and health care spending among the elderly. N. Engl. J. Med. 349(11):1048-1055.
22. Manton KG, Gu X, Lamb VL. 2006. Change in chronic disability from 1982 to 2004/2005 as measured by long-term changes in function and health in the U.S. elderly population. Proc Natl Acad Sci U S A;103(48):18374-1839.
23. Meltzer D. 1997. Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 16(1):33-64.
24. Mendelson DN, Schwartz WB. 1993. The effects of aging and population growth on health care costs. Health Aff. 12(1):119-125.
25. Nyman JA. 2004. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ. 13(5):417-427.
26. Riley GF, Lubitz JD. 2010. Long-term trends in Medicare payments in the last year of life. Health Serv. Res. 45(2):565-576.
27. Seshamani M, Gray A. 2002. The impact of ageing on expenditures in the National Health Service. Age Ageing 31(4):287-294.
28. Suhrcke M, Fumagalli E, Hancock R. 2010. Is there a wealth dividend of aging societies? Pub Health Rev. 32:377-400.
29. Thurston SJ, Heeg B, de Charro F, van Hout B. 2010. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. Curr. Med. Res. Opin. 26(3):641-651.
30. van Baal PH, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WB. 2011. Economic evaluation and the postponement of health care costs. Health Econ. 20(4):432-445.
31. Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, 2005. Yusuf S; CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 45(6):838-845.
32. Yang Z, Norton EC, Stearns SC. 2003. Longevity and health care expenditures: the real reasons older people spend more. J. Gerontol. B Psychol. Sci. Soc. Sci. 58(1):S2-10.
33. Zhang Z, Kolm P, Mosse F, Jackson J, Zhao L, Weintraub WS. 2009. Long-term cost-effectiveness of clopidogrel in STEMI patients. Int. J. Cardiol. 135(3):353-360.